IMPORTANT NOTICE: Our email addresses will soon change. Learn more >>

Zombie Aqua™ Fixable Viability Kit

Pricing & Availability
Regulatory Status
RUO
Other Names
Fixable Dye, Fixable Viability Dye
Ave. Rating
Submit a Review
Product Citations
publications
1-Zombie_Aqua_Viability_Dye_nowash_050713
One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • 1-Zombie_Aqua_Viability_Dye_nowash_050713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • b-Zombie_Aqua_Viability_Dye_032713
    One day old splenocytes were stained with Zombie Aqua™ and analyzed without fixation (blue) or analyzed after fixation and permeabilization (red). Cells alone without Zombie Aqua™ staining are indicated in black.
  • c-Zombie_Aqua_Viability_Dye_012721
    HeLa cells were treated with 20% EtOH for 20 seconds, washed twice with PBS, and then were left to recover for five minutes with cell culture media in 37°C. The cells were stained with Zombie Aqua™ (1:1000) (cyan) for 15 minutes and then fixed with 1% paraformaldehyde (PFA) for ten minutes. Nuclei were counterstained with DRAQ5 (Red) for five minutes. The image was captured with 40X objective.
See Zombie Aqua™ spectral data
Cat # Size Price Quantity Check Availability Save
423101 100 tests 72€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
423102 500 tests 268€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Zombie Aqua™ is an amine-reactive fluorescent dye that is non-permeant to live cells but permeant to cells with compromised membranes. Thus, it can be used to assess live vs. dead status of mammalian cells. Zombie Aqua™ is a polar, water-soluble dye providing very bright green fluorescence, making it suitable for use in multi-color detection.
 

Product Details
Technical Data Sheet (pdf)

Product Details

Preparation
Zombie Aqua™ Fixable Viability Kit is composed of lyophilized Zombie Aqua™ dye and anhydrous DMSO. For reconstitution, pre-warm the kit to room temperature; add 100 µl of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved. 100 tests = 1 vial of Zombie Aqua™ + DMSO, 500 tests = 5 vials of Zombie Aqua™ + DMSO.
Storage & Handling
Store kit at -20°C upon receipt. Do not open vials until needed. Once the DMSO is added to the Zombie Aqua™ dye, use immediately, or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.
Application

FC, ICFC - Quality tested
ICC - Verified

Recommended Usage

Each lot of this product is quality control tested by immunofluorescent staining with flow cytometric analysis.

For flow cytometry, the suggested dilution is 1:100-1:1000 for 1-10 million cells. For immunofluorescence microscopy, the suggested dilution is 1:1000. It is recommended that the reagent be titrated for optimal performance for each application, as optimal dosage varies with cell type.

 

Excitation Laser
Violet Laser (405 nm)
Application Notes

Zombie Aqua™ dye is excited by the violet laser and has a maximum emission of 516 nm. If using in a multi-color panel design, filter optimization may be required depending on other fluorophores used. Zombie Aqua™ dye has similar emission to Brilliant Violet 510™.

Standard Cell Staining Protocol:

  1. Prior to reconstitution, spin down the vial of lyophilized reagent in a microcentrofuge to ensure the reagent is at the bottom of the vial.
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully dissolved
  3. Wash cells with PBS buffer (no Tris buffer and protein free).
  4. Dilute Zombie Aqua™ dye at 1:100-1000 in PBS. Resuspend 1-10 x 106 cells in diluted 100 µL Zombie Aqua™ solution. To minimize background staining of live cells, titrate the amount of dye and/or number of cells per 100 µL for optimal performance. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  5. Incubate the cells at room temperature (or 4°C), in the dark, for 15-30 minutes.
  6. Wash one time with 2 mL BioLegend’s Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing serum or BSA.
  7. Continue performing antibody staining procedure as desired.
  8. Cells can be fixed with paraformaldehyde or methanol prior to permeabilization or can be analyzed without fixation.

No-wash Sequential Staining Protocol:

  1. Wash cells with PBS buffer (no Tris buffer and protein free).
  2. For reconstitution, pre-warm the kit to room temperature; add 100 µL of DMSO to one vial of Zombie Aqua™ dye and mix until fully  dissolved
  3. Determine the total µL volume of antibody cocktail previously titrated and optimized for the assay that will be added to each vial/well of cells based on a final volume of 100 µL. Subtract that antibody volume from the 100 µl total staining volume intended for the assay. In the remaining volume, dilute Zombie Aqua™ dye at 1:100-1000 in PBS as determined by prior optimization at that volume. For example, if you are adding 20 µL of antibody cocktail for a 100 µL total staining volume, use 80 µL of Zombie Aqua™ solution. Resuspend 1-10 x 106 cells in the appropriate volume of Zombie Aqua™ solution. Different cell types can have a wide degree of variability in staining based on cell size and degree of cell death.
    • Note: Don’t use Tris buffer as a diluent and be sure that the PBS does not contain any other protein like BSA or FBS.
    • Note: The amount of dye used can also influence the ability to detect apoptotic as well as live and dead cells.
  4. Incubate for 10-15 minutes at RT (or 4°C), protected from light. Without washing the cells, add the cell surface antibody cocktail and incubate for another 15-20 minutes.
  5. Add 1-2 mL Cell Staining Buffer (Cat. No. 420201) or equivalent buffer containing BSA or serum. Centrifuge to pellet.
  6. Continue with normal fixation and permeabilization procedure. If planning to skip fixation and analyze cells live, complete an additional wash step to minimize any unnecessary background of the live cells.
    • Notes: If the cell type in use cannot tolerate a protein-free environment, then titrate the Zombie Aqua™ dye in the presence of the same amount of BSA/serum as will be present in the antibody staining procedure. A higher amount of Zombie Aqua™ may be required since the BSA/serum will react with and bind up some proportion of the Zombie Aqua™.
Additional Product Notes

View more applications data using this product to validate Veri-Cells™ lyophilized control cells and to study dendritic cell subsets.

Application References
  1. Vom Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  2. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  3. Price PJ, et al. 2014. J Virol. 88:10840. PubMed
  4. Schmid MA, et al. 2014. PLoS Pathog. 10:1004541. PubMed
  5. Cohen SB, et al. 2015. J Immunol. 194:210. PubMed
  6. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  7. Price PJ, et al. 2015. J Immunol. 194:1164. PubMed
  8. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  9. Tzeng A, et al. 2015. PNAS. 112:3320. PubMed
  10. Peres AG, et al. 2015. Infect Immun. 83:1587. PubMed
  11. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
Product Citations
  1. Nuccitelli R, et al. 2017. J Immunother Cancer . 10.1186/s40425-017-0234-5. PubMed
  2. Kaczanowska S, et al. 2017. Cancer Res. . 10.1158/0008-5472.CAN-17-0653. PubMed
  3. Gálvez-Cancino F, et al. 2018. Oncoimmunology. 7:e1442163. PubMed
  4. Contijoch EJ et al. 2019. eLife. 8 pii: e40553. PubMed
  5. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  6. Eiva MA, et al. 2022. Eur J Immunol. 52:96. PubMed
  7. Duraiswamy J, et al. 2021. Cancer Cell. 39:1623. PubMed
  8. Herz J, et al. 2021. Neuron. 109:3609. PubMed
  9. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  10. Miek L, et al. 2022. Immunology. 166:47. PubMed
  11. Wolf B, et al. 2022. Immunology. 166:380. PubMed
  12. Iberg CA, et al. 2022. Cell Rep. 39:110657. PubMed
  13. Shcheynikov N, et al. 2022. Hepatology. 76:1248. PubMed
  14. Tang Q, et al. 2022. Mol Ther. 30:2709. PubMed
  15. Adam-Artigues A, et al. 2022. Sci Adv. 8:eabk2746. PubMed
  16. Yang K, et al. 2022. Sci Immunol. 7:eabn2888. PubMed
  17. Sugimoto S, et al. 2022. Nat Metab. 4:775. PubMed
  18. Ma T, et al. 2022. Elife. 11: . PubMed
  19. Benedetti V, et al. 2022. Sci Adv. 8:eabn3986. PubMed
  20. Guasconi L, et al. 2022. J Fungi (Basel). 8: . PubMed
  21. Zhu J, et al. 2022. Research (Wash D C). 2022:9816272. PubMed
  22. Shen Z, et al. 2022. EBioMedicine. 85:104285. PubMed
  23. Martínez-Sabadell A, et al. 2022. Cell Rep. 41:111430. PubMed
  24. Gao Y, et al. 2022. Cell Res. 32:1086. PubMed
  25. Dhar R, et al. 2022. Int J Mol Med. 50: . PubMed
  26. Balood M, et al. 2022. Nature. 611:405. PubMed
  27. Yoo HJ, et al. 2022. Cell Rep. 41:111598. PubMed
  28. Liang Y, et al. 2022. Theranostics. 12:7729. PubMed
  29. Rico-Llanos G, et al. 2022. Front Immunol. 13:1054962. PubMed
  30. Chen W, et al. 2022. Front Immunol. 13:1046426. PubMed
  31. Zia S, et al. 2022. Mol Neurodegener. 17:82. PubMed
  32. Zhuang L, et al. 2022. J Am Heart Assoc. 11:e027228. PubMed
  33. Pleuger C, et al. 2022. Elife. 11: . PubMed
  34. Shen W, et al. 2023. Dis Model Mech. 16: . PubMed
  35. Perveen R, et al. 2023. Hum Cell. 36:583. PubMed
  36. Krammer S, et al. 2022. Cells. 12: . PubMed
  37. Chan L, et al. 2022. Cells. 12: . PubMed
  38. Cousin N, et al. 2022. Cells. 12: . PubMed
  39. Rice CM, et al. 2023. Life Sci Alliance. 6: . PubMed
  40. Zhao Q, et al. 2023. Nutrients. 15: . PubMed
  41. Romine KA, et al. 2023. Leukemia. 37:580. PubMed
  42. Ai L, et al. 2023. Cell Discov. 9:9. PubMed
  43. Gong HH, et al. 2023. Front Immunol. 13:1089064. PubMed
  44. Gonçalves R, et al. 2023. iScience. 26:105972. PubMed
  45. Liu G, et al. 2023. Commun Biol. 6:102. PubMed
  46. Li H, et al. 2023. Front Immunol. 13:1056447. PubMed
  47. Lutz EA, et al. 2022. PNAS Nexus. 1:pgac244. PubMed
  48. Badenes M, et al. 2023. Life Sci Alliance. 6: . PubMed
  49. Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed
  50. Kang J, et al. 2023. JCI Insight. 8: . PubMed
  51. Chan L, et al. 2023. Int J Mol Sci. 24: . PubMed
  52. Babl N, et al. 2023. Front Oncol. 13:1107484. PubMed
  53. Drummer C, et al. 2023. Front Immunol. 14:1113883. PubMed
  54. Li Y, et al. 2022. Brain Behav Immun. 101:1. PubMed
  55. Ryan CB, et al. 2022. Neurobiol Dis. 163:105608. PubMed
  56. Fahrner JE, et al. 2022. Cancer Discov. 12:958. PubMed
  57. Blair TC, et al. 2022. Life Sci Alliance. 5:. PubMed
  58. Ko J, et al. 2022. Nat Biotechnol. 40:1654. PubMed
  59. Zhu Z, et al. 2022. Clin Cancer Res. 28:4820. PubMed
  60. Lutz EA, et al. 2022. Proc Natl Acad Sci U S A. 119:e2205983119. PubMed
  61. Bermea KC, et al. 2022. J Vis Exp. . PubMed
  62. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  63. Frost JN, et al. 2022. Sci Adv. 8:eabq5384. PubMed
  64. Schuhmacher J, et al. 2022. Cells. 11:. PubMed
  65. Cruz-Reséndiz A, et al. 2022. Front Immunol. 13:1057499. PubMed
  66. Johnson SD, et al. 2022. Front Immunol. 13:1001727. PubMed
  67. Egli J, et al. 2022. MAbs. 14:2143009. PubMed
  68. Lao L, et al. 2023. Cancer Immunol Res. 11:320. PubMed
  69. Cai Z, et al. 2023. Adv Sci (Weinh). 10:e2207155. PubMed
  70. Yang Y, et al. 2023. MBio. 14:e0328522. PubMed
  71. Gao L, et al. 2023. J Nanobiotechnology. 21:56. PubMed
  72. Jun SH, et al. 2023. Nat Commun. 14:982. PubMed
  73. Fernandes S, et al. 2023. iScience. 26:106071. PubMed
  74. Aso K, et al. 2023. Nat Commun. 14:984. PubMed
  75. Medina S, et al. 2023. Water (Basel). 15:. PubMed
  76. Gupta T, et al. 2023. Front Immunol. 14:1044703. PubMed
  77. Xu K, et al. 2023. Elife. 12:. PubMed
  78. Battistello E, et al. 2023. Mol Cell. 83:1216. PubMed
  79. Zhang J, et al. 2023. Front Immunol. 14:1091541. PubMed
  80. Harpur CM, et al. 2023. Clin Transl Immunology. 12:e1443. PubMed
  81. Pankhurst TE, et al. 2023. Cell Rep. 42:112310. PubMed
  82. Ahmed O, et al. 2023. Bioelectron Med. 9:6. PubMed
  83. Freitag PC, et al. 2023. Mol Ther Methods Clin Dev. 29:120. PubMed
  84. Palakurthi B, et al. 2023. Nat Commun. 14:2109. PubMed
  85. Madar J, et al. 2023. Nat Commun. 14:2158. PubMed
  86. Consonni FM, et al. 2023. Front Immunol. 14:1168455. PubMed
  87. Fang Y, et al. 2023. Front Immunol. 14:1162004. PubMed
  88. Chaturvedi S, et al. 2023. Cell. 186:2036. PubMed
  89. Ximerakis M, et al. 2023. Nat Aging. 3:327. PubMed
  90. Liao Y, et al. 2023. ACS Omega. 8:15217. PubMed
  91. Menevse AN, et al. 2023. Acta Neuropathol Commun. 11:75. PubMed
  92. Liu JC, et al. 2023. Int J Mol Sci. 24:. PubMed
  93. Tang L, et al. 2023. Front Immunol. 14:1145441. PubMed
  94. Zhang Z, et al. 2023. Aging Dis. 14:966. PubMed
  95. Malik JR, et al. 2023. Int J Mol Sci. 24:. PubMed
  96. Feng X, et al. 2023. Nat Commun. 14:3208. PubMed
  97. Komoto S, et al. 2023. Cancers (Basel). 15:. PubMed
  98. Zhou R, et al. 2022. EBioMedicine. 75:103762. PubMed
  99. Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed
  100. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  101. Castle AR, et al. 2022. PLoS One. 17:e0269342. PubMed
  102. Healy LM, et al. 2020. Glia. 68:811. PubMed
  103. Buchanan MW, et al. 2021. J Orthop Res. 39:1710. PubMed
  104. Bussières-Marmen S, et al. 2017. Cell Mol Immunol. 10.1038/cmi.2016.72. PubMed
  105. Darzianiazizi M, et al. 2020. Int J Mol Sci. 21:00. PubMed
  106. Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed
  107. Lindner SE, et al. 2020. Immunohorizons. 0.356944444. PubMed
  108. Tasker C, et al. 2021. AAPS J. 23:26. PubMed
  109. Lin C, et al. 2020. Cancer Immunol Res. 632:8. PubMed
  110. Kim J, et al. 2021. Front Cell Neurosci. 638098:15. PubMed
  111. Grigsby SM, et al. 2021. Cancers (Basel). 13:. PubMed
  112. Rueschenbaum S, et al. 2021. Front Immunol. 11:581352. PubMed
  113. Fantone K, et al. 2021. Pathogens. 10:. PubMed
  114. Vella JL, et al. 2021. Life Sci Alliance. 4:. PubMed
  115. Fujii H, et al. 2015. PLoS One. 10: 0133216. PubMed
  116. Michelet X, et al. 2015. J Immunol. 194:2079. PubMed
  117. Vanderleyden I, et al. 2020. Cell Rep. 30:611. PubMed
  118. Böttcher M, et al. 2018. Oncoimmunology. 7:e1445454. PubMed
  119. Jeevan-Raj B, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.06.071. PubMed
  120. Lam B, et al. 2021. Cell Rep. 37:109838. PubMed
  121. Ferrere G, et al. 2021. JCI Insight. 6:. PubMed
  122. Chaturvedi S, et al. 2022. Cell. 185:2086. PubMed
  123. Volta V, et al. 2021. Nat Commun. 12:6979. PubMed
  124. Seki SM, et al. 2020. Sci Signal. :13. PubMed
  125. Krausgruber T, et al. 2020. Nature. 583:296. PubMed
  126. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
  127. Price P, et al. 2014. J Virol. 88:10840. PubMed
  128. Tzeng A, et al. 2015. Proc Natl Acad Sci U S A. 112:3320. PubMed
  129. Yamaguchi M, et al. 2016. J Leukoc Biol. 100: 131 - 141. PubMed
  130. Swee L, et al. 2016. Open Bio. 6: 160293. PubMed
  131. Kobayashi T, et al. 2019. Cell. 176:982. PubMed
  132. Gálvez-Cancino F, et al. 2017. Vaccine. 10.1016/j.vaccine.2017.06.041. PubMed
  133. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  134. Barry KC, et al. 2018. Nat Med. 24:1178. PubMed
  135. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  136. Shin HS, et al. 2022. Sci Rep. 12:17605. PubMed
  137. Meyer Zu Natrup C, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  138. Toomer G, et al. 2022. Viruses. 14:. PubMed
  139. Kiritsy MC, et al. 2021. Elife. 10:. PubMed
  140. Blake SJ, et al. 2021. Cell Rep Med. 2:100464. PubMed
  141. Lo MW, et al. 2022. Clin Transl Immunology. 11:e1413. PubMed
  142. Lownik JC, et al. 2020. Biochem Biophys Res Commun. 522:442. PubMed
  143. Alberts-Grill N, et al. 2016. J Immunol. 197(12):4651-4662. PubMed
  144. Clement M, et al. 2016. PLoS Pathog. 12:e1006050. PubMed
  145. Torre S, et al. 2016. Nat Immunol. 10.1038/ni.3581. PubMed
  146. Bittner-Eddy P, et al. 2016. J Immunol. 197: 1435 - 1446. PubMed
  147. Berg J, et al. 2013. J Exp Med. 210:2803. PubMed
  148. Meehan S, et al. 2019. Commun Biol. 2:229. PubMed
  149. Tan L, et al. 2019. Cell Rep. 27:3657. PubMed
  150. Hartsough EJ, et al. 2019. Cell Death Dis. 10:281. PubMed
  151. Chattopadhyay A, et al. 2018. Sci Rep. 8:9032. PubMed
  152. Martrus G, et al. 2017. PLoS One.. 10.1371/journal.pone.0182532. PubMed
  153. Setten E, et al. 2022. Nat Commun. 13:6499. PubMed
  154. Liu Y, et al. 2022. Cancer Discov. :. PubMed
  155. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  156. Munoz MA, et al. 2021. Elife. 10:. PubMed
  157. Gong W, et al. 2021. Oncoimmunology. 10:1997385. PubMed
  158. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
  159. Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed
  160. van der Heide V, et al. 2022. Cell Rep. :110508. PubMed
  161. Witkowski M, et al. 2021. Nature. 600:295. PubMed
  162. Deng X, et al. 2021. Open Biol. 11:200340. PubMed
  163. Yu X, et al. 2021. Nature. 594:560. PubMed
  164. Park JJ, et al. 2021. Nat Commun. 12:1222. PubMed
  165. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  166. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
  167. Li LH, et al. 2020. Antiviral Res. 104929:183. PubMed
  168. Jenull S, et al. 2021. Cell Reports. 36(3):109406. PubMed
  169. Gruber T, et al. 2020. JCI Insight. 5:00. PubMed
  170. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  171. Neidleman J, et al. 2020. Elife. 9:00. PubMed
  172. Peres A, et al. 2015. Infect Immun . 83:1587. PubMed
  173. Yoshida N, et al. 2016. Nat Commun. 7: 12993. PubMed
  174. Fang V, et al. 2016. Nat Immunol. 18:15-25. PubMed
  175. Wright AKA, et al. 2017. J Allergy Clin Immunol. 140:1430. PubMed
  176. Botuyan MV, et al. 2018. Nat Struct Mol Biol. 25:591. PubMed
  177. Martínez-Sabadell A, et al. 2022. STAR Protoc. 3:101712. PubMed
  178. Tu X, et al. 2022. Nat Commun. 13:6977. PubMed
  179. Mathur S, et al. 2021. JCI Insight. 6:. PubMed
  180. Pedersen JG, et al. 2021. Front Microbiol. 12:763030. PubMed
  181. Almutairi F, et al. 2021. Front Immunol. 12:772288. PubMed
  182. Bresque M, et al. 2022. J Biol Chem. :101711. PubMed
  183. Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed
  184. Mukherjee D, et al. 2022. Nat Commun. 13:3747. PubMed
  185. Ruetsche D, et al. 2022. Cells. 11:. PubMed
  186. Hagen SH, et al. 2020. Cell Rep. 33:108485. PubMed
  187. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  188. Darzianiazizi M, et al. 2021. Cytokine X. 3:100053. PubMed
  189. Go DM, et al. 2021. Cell Mol Gastroenterol Hepatol. 12:715. PubMed
  190. Amberg N, et al. 2016. J Invest Dermatol. 136:2140-2149. PubMed
  191. Cunningham C, et al. 2016. PLoS Pathog. 12: 1005356. PubMed
  192. Schmitt N, et al. 2015. Mol Cancer Ther. 14: 2103-2111. PubMed
  193. Britton GJ et al. 2019. Immunity. 50(1):212-224 . PubMed
  194. Grozio A, et al. 2019. Nat Metab. 1:47. PubMed
  195. Ramsey HE, et al. 2018. Cancer Discov. 8:1566. PubMed
  196. Parameswaran P, et al. 2017. Cell Host Microbe. 10.1016/j.chom.2017.08.003. PubMed
  197. Chen Z, et al. 2022. Theranostics. 12:6242. PubMed
  198. Tang JJ, et al. 2022. Cell Rep. 39:110987. PubMed
  199. Luo X, et al. 2021. J Biol Chem. 297:101098. PubMed
  200. Johansen AZ, et al. 2022. Pharmaceutics. 14:. PubMed
  201. Rogawski DS, et al. 2021. Nat Commun. 12:2792. PubMed
  202. Cousin N, et al. 2021. Cancer Res. 81:4133. PubMed
  203. Paiva RS, et al. 2021. Eur J Immunol. 51:1968. PubMed
  204. Denkers S 2015. J Immunol. 195: 2754-2762. PubMed
  205. Garcia-Bates T, et al. 2016. J Immunol. 196: 2870 - 2878. PubMed
  206. Davidson S, et al. 2016. EMBO Mol Med. 8: 1099 - 1112. PubMed
  207. Valbuena Perez JV, et al. 2020. Aging Cell. 19:e13156. PubMed
  208. Sellau J, et al. 2020. Nat Commun. 2.860416667. PubMed
  209. Ceholski D, et al. 2017. Stem Cell Res. 10.1016/j.scr.2017.06.015. PubMed
  210. Metzemaekers M, et al. 2017. Int J Mol Sci. 10.3390/ijms18071513. PubMed
  211. Tien S, et al. 2017. PLoS One. 10.1371/journal.pone.0181338. PubMed
  212. Alvisi G, et al. 2022. Methods Mol Biol. 2559:243. PubMed
  213. Li FJ, et al. 2022. PLoS One. 17:e0277019. PubMed
  214. Zheng S, et al. 2022. Blood Cancer Discov. 3:103. PubMed
  215. Yang K, et al. 2022. J Clin Invest. 132:. PubMed
  216. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
  217. Tang Y, et al. 2021. Cancer Discov. 11:3142. PubMed
  218. Borst L, et al. 2022. Int J Cancer. 150:688. PubMed
  219. Chan JA, et al. 2020. Cell Rep Med. 1:100157. PubMed
  220. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  221. Jordan PM, et al. 2020. Cell Rep. 33:108247. PubMed
  222. Doty DT, et al. 2020. Int J Mol Sci. 21:00. PubMed
  223. Dillon SM, et al. 2020. Bio Protoc. e3486:10. PubMed
  224. Pantelyushin S, et al. 2021. Cancers (Basel). :13. PubMed
  225. Alsaleh G, et al. 2020. Elife. 9: . PubMed
  226. Stuani L, et al. 2021. J Exp Med. 218:. PubMed
  227. OlguÍn-Alor R, et al. 2016. PLoS One. 11:e0167813. PubMed
  228. Crisci E, et al. 2016. J Virol. 90: 4939 - 4950. PubMed
  229. Hansmann L, et al. 2015. Cancer Immunol Res. 3:650. PubMed
  230. Chakraborty A, et al. 2020. Cell Rep. 32:108179. PubMed
  231. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  232. Kruse S, et al. 2018. Oncoimmunology. 8:e1524694. PubMed
  233. Louveau A, et al. 2018. Curr Protoc Immunol. 121:1. PubMed
  234. Wilmore JR et al. 2018. Cell host & microbe. 23(3):302-311 . PubMed
  235. Joshi N and Werner S. 2017. PLoS One. 10.1371/journal.pone.0187162. PubMed
  236. Natoli M, et al. 2022. J Immunother Cancer. 10:. PubMed
  237. Wang Z, et al. 2022. Nat Commun. 13:5447. PubMed
  238. Romine KA, et al. 2021. Blood Cancer Discov. 2:518. PubMed
  239. Romine KA, et al. 2021. Cancer Discov. . PubMed
  240. Mehta AK, et al. 2021. Nat Cancer. 2:66. PubMed
  241. Li Y, et al. 2021. Brain Behav Immun. 91:267. PubMed
  242. Karagianni AE, et al. 2021. Sci Rep. 11:14292. PubMed
  243. Korangath P, et al. 2020. Bio Protoc. 10:e3822. PubMed
  244. Amanat F, et al. 2021. Cell. 184:3936. PubMed
  245. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  246. Audiger C, et al. 2020. J Immunol. 205:121. PubMed
  247. Fernandez-Castaneda A, et al. 2020. Acta Neuropathol. 139:365. PubMed
  248. Köchl R, et al. 2020. Elife. 9:00. PubMed
  249. Honarpisheh P, et al. 2020. J Neuroinflammation. 0.9625. PubMed
  250. Yang Y, et al. 2016. Nucleic Acids Res. 44: 4174 - 4188. PubMed
  251. Coria L, et al. 2016. J Immunol. 196: 4014 - 4029. PubMed
  252. Yamazaki T, et al. 2020. Oncoimmunology. 9:1721810. PubMed
  253. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  254. Kallert S, et al. 2017. Nature Communications. 10.1038/ncomms15327. PubMed
  255. Rechtien A, et al. 2017. Cell Rep. 10.1016/j.celrep.2017.08.023. PubMed
  256. Reed J, et al. 2020. Bio Protoc. 10:e3607. PubMed
  257. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  258. Hu H, et al. 2021. Cancer Immunol Res. 9:1298. PubMed
  259. Breen EC, et al. 2022. iScience. 25:104488. PubMed
  260. Zhang F, et al. 2020. EMBO Mol Med. e12034:12. PubMed
  261. Xing J, et al. 2021. Nat Commun. 12:2681. PubMed
  262. Hildebrand KM, et al. 2021. PLoS One. 16:e0253864. PubMed
  263. Littwitz-Salomon E, et al. 2021. Nat Commun. 12:5376. PubMed
  264. Andriessen E, et al. 2016. EMBO Mol Med. 8(12):1366-1379. PubMed
  265. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  266. Krämer B, et al. 2016. PLoS One. 11: 0162068. PubMed
  267. Schmid M, et al. 2016. PLoS One. 12: 1005676. PubMed
  268. Contreras F, et al. 2016. J Immunol. 196: 4143 - 4149. PubMed
  269. Larmonier C, et al. 2016. J Biol Chem. 291: 8918-8930. PubMed
  270. Lim X, et al. 2016. Proc Natl Acad Sci U S A. 113: 1498 - 1505. PubMed
  271. Carmona SJ, et al. 2020. Oncoimmunology. 9:1737369. PubMed
  272. Haloul M, et al. 2019. Sci Rep. 9:14050. PubMed
  273. Engelbertsen D, et al. 2019. Sci Rep. 9:10608. PubMed
  274. Freire DM, et al. 2019. Mol Cell. 73:1282. PubMed
  275. Scarneo SA, et al. 2022. Sci Rep. 12:18091. PubMed
  276. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  277. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  278. Luo J, et al. 2022. J Nanobiotechnology. 20:228. PubMed
  279. Shen J, et al. 2022. Front Immunol. 13:762580. PubMed
  280. Momin N, et al. 2022. Nat Commun. 13:109. PubMed
  281. Giesen D, et al. 2020. Clin Cancer Res. 26:3999. PubMed
  282. Tsang M, et al. 2020. Am J Pathol. 190:206. PubMed
  283. Dieterich LC, et al. 2020. Angiogenesis. 1.24375. PubMed
  284. Brugat T, et al. 2017. Nat Microbiol. 2:16276. PubMed
  285. Cohen S, et al. 2015. J Immunol. 194:210. PubMed
  286. Price P, et al. 2015. J Immunol. 194:1164. PubMed
  287. Chattopadhyay A, et al. 2016. J Lipid Res. 57: 832 - 847. PubMed
  288. Dutzan N, et al. 2017. Immunity. 46(1):133-147. PubMed
  289. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  290. Zebertavage LK, et al. 2020. Sci Rep. 10:7376. PubMed
  291. Rhys HI, et al. 2018. EBioMedicine. 29:60. PubMed
  292. Fragniere AMC, et al. 2019. Sci Rep. 9:2288. PubMed
  293. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
  294. Neal JT, et al. 2018. Cell. 175:1972. PubMed
  295. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  296. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  297. Bankova AK, et al. 2022. Transplant Cell Ther. . PubMed
  298. Sinha SR, et al. 2020. Cell Host Microbe. 27:659. PubMed
  299. Bullard BL, et al. 2022. NPJ Vaccines. 7:65. PubMed
  300. Rossignol J, et al. 2022. iScience. 25:104353. PubMed
  301. Karagianni A, et al. 2022. Front Oncol. 12:929498. PubMed
  302. Castro JT, et al. 2022. Nat Commun. 13:4831. PubMed
  303. Coden ME, et al. 2020. J Immunol. 204:438. PubMed
  304. James KR, et al. 2020. Nat Immunol. 1.113194444. PubMed
  305. Lewandowski JP, et al. 2020. Genome Biol. 1.039583333. PubMed
  306. Sabree SA, et al. 2021. J Immunother Cancer. 9: . PubMed
  307. Fu Z, et al. 2021. Nat Commun. 12:4462. PubMed
  308. Pan W, et al. 2021. J Immunol. 206:1719. PubMed
  309. Ryan P, et al. 2016. Proc Natl Acad Sci U S A. 113(50):14378-14383. PubMed
  310. LM S, et al. 2016. Cell Rep. 16(12): 3286-96. PubMed
  311. Tron AE, et al. 2018. Nat Commun. 9:5341. PubMed
  312. Collin R, et al. 2017. J Immunol. 10.4049/jimmunol.1600789. PubMed
  313. Teng Y, et al. 2017. J Hematol Oncol. 10.1186/s13045-017-0485-0. PubMed
  314. Huo Y, et al. 2022. Front Immunol. 13:983116. PubMed
  315. Clark GC, et al. 2022. Front Oncol. 12:913656. PubMed
  316. Xiao L, et al. 2021. Clin Cancer Res. 27:4338. PubMed
  317. Rocha-Resende C, et al. 2021. J Mol Cell Cardiol. 157:98. PubMed
  318. Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed
  319. Barington L, et al. 2022. Cells. 11:. PubMed
  320. Bendtsen SK, et al. 2022. Oncoimmunology. 11:2026020. PubMed
  321. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  322. Huo Y, et al. 2021. BMC Genomics. 22:145. PubMed
  323. Madsen A, et al. 2020. Immunity. 53:852. PubMed
  324. Li H, et al. 2021. Adv Sci (Weinh). 2001596:8. PubMed
  325. Ritzel RM, et al. 2021. Glia. 69:746. PubMed
  326. Parayath NN, et al. 2020. Nat Commun. 4.680555556. PubMed
  327. Wang L, et al. 2020. EMBO J. 39:e104514. PubMed
  328. Schmid M, Harris E 2014. PLoS Pathog. 10:1004541. PubMed
  329. Madsen D, et al. 2017. Cell Rep.. 10.1016/j.celrep.2017.12.011. PubMed
  330. Becker JR, et al. 2018. Nat Commun. 9:5406. PubMed
  331. Suan D et al. 2017. Immunity. 47(6):1142-1153 . PubMed
  332. Miller JE, et al. 2021. JCI Insight. 6:. PubMed
  333. Wen T, et al. 2022. Cancer Immunol Res. 10:162. PubMed
  334. Lee GJ, et al. 2022. Oncoimmunology. 11:2015170. PubMed
  335. Andriessen EMMA, et al. 2021. EMBO Mol Med. 13:e11754. PubMed
  336. Shibata H, et al. 2021. Oncoimmunology. 10:1958589. PubMed
  337. Constant DA, et al. 2022. Immunohorizons. 6:416. PubMed
  338. Li J, et al. 2022. Nat Commun. 13:4032. PubMed
  339. Taylor D, et al. 2022. Front Immunol. 13:936129. PubMed
  340. Yoder A, et al. 2017. PLoS Pathog. 13(2):e1006226. PubMed
  341. Davey M, et al. 2017. Nat Commun. 10.1038/ncomms14760. PubMed
  342. Fang H, et al. 2020. Nat Commun. 4.661805556. PubMed
  343. Hagen SH, et al. 2021. STAR Protocols. 2(3):100641. PubMed
  344. Daemen S, et al. 2021. STAR Protoc. 2:100511. PubMed
  345. Santos NB, et al. 2021. PLoS Pathog. 17:e1009381. PubMed
  346. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  347. Concha-Benavente F, et al. 2016. Cancer Res . 76: 1031 - 1043. PubMed
  348. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
  349. Ogrinc Wagner A, et al. 2019. PLoS One. 14:e0210998. PubMed
  350. Zwick M, et al. 2019. Front Immunol. 10:222. PubMed
  351. Li H, et al. 2022. Front Immunol. 13:946202. PubMed
  352. Sakamoto K, et al. 2021. Immunity. 54:2321. PubMed
  353. McCallion A, et al. 2022. Front Immunol. 13:961599. PubMed
  354. Ye Q, et al. 2022. NPJ Vaccines. 7:84. PubMed
  355. Alice AF, et al. 2021. Sci Rep. 11:16347. PubMed
  356. Singh AK, et al. 2022. Nat Commun. 13:878. PubMed
  357. Kumar S, et al. 2022. Gut. . PubMed
  358. Bent EH, et al. 2021. Nat Commun. 12:6218. PubMed
  359. Manouchehri N, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
  360. Nylund P, et al. 2021. Cell Death Dis. 12:167. PubMed
  361. Hofmann J, et al. 2021. Front Immunol. 11:599495. PubMed
  362. Kakiyama G, et al. 2020. J Lipid Res. 61:1629. PubMed
  363. de Winde CM, et al. 2021. J Cell Sci. 134: . PubMed
  364. Leong Y, et al. 2016. Nat Immunol. 17:1187-1196. PubMed
  365. Ohs I, et al. 2016. Nat Commun. 7:13708. PubMed
  366. Schuldt N, et al. 2017. The Journal of Immunology. 10.4049/jimmunol.1700406. PubMed
  367. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
  368. Dawson NA, et al. 2019. JCI Insight. 4:6. PubMed
  369. Vigeland CL, et al. 2019. Physiol Rep. 7:e14019. PubMed
  370. Arenas EJ, et al. 2021. Nat Commun. 12:1237. PubMed
  371. Rodriguez E, et al. 2021. Cancers (Basel). 13:. PubMed
  372. Dholakia J, et al. 2022. Gynecol Oncol. 164:170. PubMed
  373. Wegrecki M, et al. 2022. Nat Commun. 13:3872. PubMed
  374. Peng Z, et al. 2022. J Neuroinflammation. 19:186. PubMed
  375. Brockman QR, et al. 2022. JCI Insight. :. PubMed
  376. Lee SH, et al. 2022. Nat Commun. 13:5461. PubMed
  377. Lu YJ, et al. 2021. Cell Rep. 36:109696. PubMed
  378. Ju X, et al. 2016. J Immunol. 197(12):4613-4625. PubMed
  379. Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed
  380. Gouwy M, et al. 2016. PLoS One. 11:e0166006. PubMed
  381. McGuire V, et al. 2016. Sci Rep. 6:31159. PubMed
  382. Comte D, et al. 2016. Proc Natl Acad Sci U S A. 113: 9321 - 9326. PubMed
  383. Carpenter S, et al. 2016. PLoS Pathog. 12: 1005380. PubMed
  384. Jerby–Arnon L, et al. 2018. Cell. 175:984. PubMed
  385. Pfirschke C, et al. 2020. Cell Rep. 32:108164. PubMed
  386. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  387. Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed
  388. Mello AM, et al. 2022. Oncogenesis. 11:56. PubMed
  389. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  390. Li M, et al. 2021. Mol Biomed. 2:41. PubMed
  391. Milich LM, et al. 2021. J Exp Med. 218:. PubMed
  392. Alhudaithi SS, et al. 2020. Mol Pharm. 17:4691. PubMed
  393. Fucà G, et al. 2021. J Immunother Cancer. 9:. PubMed
  394. Egedal JH, et al. 2021. Mucosal Immunol. 14:1203. PubMed
  395. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  396. Abdelsamed HA, et al. 2020. Nat Immunol. 1.276388889. PubMed
  397. Rocha-Resende C, et al. 2020. JCI Insight. 5:00. PubMed
  398. Luo X, et al. 2020. J Clin Invest. 130:1635. PubMed
  399. Peter Morawski, Chen-Feng Qi, Silvia Boll 2017. Sci Rep. 7:40838. PubMed
  400. Antsiferova M, et al. 2017. EMBO Mol Med. 9(1):27-45. PubMed
  401. Martini E, et al. 2016. Cell Rep. 14:1062-1073. PubMed
  402. Weiss G, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.104. PubMed
  403. Dhimolea E, et al. 2021. Cancer Cell. 39:240. PubMed
  404. Li Y, et al. 2022. Theranostics. 12:5364. PubMed
  405. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  406. Patel C, et al. 2022. Curr Protoc. 2:e400. PubMed
  407. Neidleman J, et al. 2017. PLoS Pathog. 13(2):e1006163. PubMed
  408. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
  409. Yang C, et al. 2020. Cell Host Microbe. 467:27. PubMed
  410. Blair TC, et al. 2020. J Immunol. 204:3416. PubMed
  411. Farooq F, et al. 2016. Sci Rep. 6:27944. PubMed
  412. Li Y, et al. 2020. Theranostics. 10:11376. PubMed
  413. Tomlinson JE, et al. 2018. J Neuroinflammation. 0.753472222. PubMed
  414. Padhye A, et al. 2019. Sci Rep. 9:4819. PubMed
  415. Yuan C, et al. 2018. iScience. 11:13. PubMed
  416. Tiberti S, et al. 2022. Nat Commun. 13:6752. PubMed
  417. Bozoglu T, et al. 2022. Adv Sci (Weinh). 9:e2103867. PubMed
  418. Lau P, et al. 2022. Cell Mol Immunol. :. PubMed
  419. van Loon K, et al. 2022. Cancers (Basel). 14:. PubMed
  420. Singh SS, et al. 2022. Clin Transl Immunology. 11:e1396. PubMed
  421. Sakamoto K, et al. 2022. STAR Protoc. 3:101052. PubMed
  422. Verma M, et al. 2021. J Exp Med. 218:. PubMed
  423. Van Winkle JA, et al. 2020. J Virol. 94:. PubMed
  424. Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed
  425. Kohn M, et al. 2021. Front Immunol. 626627:12. PubMed
  426. Salahudeen AA, et al. 2020. bioRxiv. . PubMed
  427. Krogmann A, et al. 2016. PLoS One. 11: 0146326. PubMed
  428. Johns S, et al. 2016. Circ Res . 119: 210 - 221. PubMed
  429. Pflügler S, et al. 2020. Commun Biol. 3:252. PubMed
  430. Dai H, et al. 2017. J Immunol. 10.4049/jimmunol.1700418. PubMed
  431. Luo ZW, et al. 2021. Int J Nanomedicine. 16:2949. PubMed
  432. Xu L, et al. 2022. Front Immunol. 13:841141. PubMed
  433. Spath S, et al. 2022. iScience. 25:104998. PubMed
  434. Cho SX, et al. 2020. Nat Commun. 4.481944444. PubMed
  435. Filippo Buono M, et al. 2020. Cells. 9:00. PubMed
  436. Friedrich V, et al. 2021. Gut Microbes. 13:1. PubMed
  437. Jiang M, et al. 2021. Front Pharmacol. 12:657486. PubMed
  438. Henkle TR, et al. 2021. Cancer Res. 81:4560. PubMed
  439. Schaller MA, et al. 2021. JCI Insight. 6:e148003. PubMed
  440. Pan L, et al. 2021. Stem Cell Res Ther. 12:496. PubMed
  441. Hatfield J, Brown M 2015. Cell Immunol. . PubMed
  442. Li J, et al. 2015. Cancer Res. 75:508. PubMed
  443. Binnewies M, et al. 2019. Cell. 177:556. PubMed
  444. Orozco SL, et al. 2019. Cell Rep. 28:2275. PubMed
  445. Kimura K, et al. 2018. Nat Commun. 9:17. PubMed
  446. Wang CJH, et al. 2022. J Biol Chem. :102714. PubMed
  447. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  448. Wang H, et al. 2022. J Cancer. 13:2126. PubMed
  449. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
  450. Khurana P, et al. 2021. Front Immunol. 12:700374. PubMed
  451. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  452. Chakraborty A, et al. 2021. Biomaterials. 273:120796. PubMed
  453. Feng Y, et al. 2022. EClinicalMedicine. 43:101226. PubMed
  454. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  455. Tee YC, et al. 2021. FASEB Bioadv. 3:829. PubMed
  456. Xia L, et al. 2021. Cancer Immunol Res. 9:707. PubMed
  457. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
  458. Schreurs RRCE, et al. 2021. Mucosal Immunology. 14(3):605-614. PubMed
  459. Workel HH, et al. 2020. Int J Mol Sci. 21:00. PubMed
  460. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  461. Salahudeen AA, et al. 2020. Nature. 588:670. PubMed

Antigen Details

Biology Area
Apoptosis/Tumor Suppressors/Cell Death, Cell Biology, Neuroscience
Gene ID
NA

Related FAQs

Is Zombie Aqua™ an equivalent to cell labeling and tracer dyes such as CellTrace™ Violet and CFSE?

Zombie Aqua™ is not a direct equivalent to such dyes because their mechanism of action and scope of application are entirely different.

I am concerned about the spillover I am observing from the Zombie dye into its neighboring channels.
Rule of thumb with Zombie dyes is to titrate them down as much as possible to fit your application. This should potentially help with spillover. Secondly, Zombie positive events represent dead cells and are typically gated out from analysis.
How does the performance of your Zombie dye compare with competitors?

Zombie dyes have been tested against other leading competitors' fixable viability kits and given comparable results. We also highly recommend that you titrate down the amount of each dye used in order to best match the negative signals of your unstained sample and MFI- (mean fluorescence intensity) stained samples.

Can I use methanol/ethanol for fixation after using a Zombie dye?

Yes, most fixation reagents are fine to be used with Zombie dyes. However, it should be noted that Zombie dyes can still be sensitive to reactive oxygen species. Light exposure or reagents with hydrogen peroxide can lead to free radical formation, affecting fluorescence.

Can Zombie be used to determine bacteria, yeast viability?
We have not tested in house bacterial or yeast viability using Zombie dyes. It is not clear whether the difference between surface and intracellular signals will be significantly different in case of non mammalian cells.
Can I use Zombie with cells suspension containing serum?
Serum is full of proteins which will sequester the dye and thereby reducing its effective concentration. The basic rule of thumb with zombie is to titrate it based on your specific condition. Titration also helps reduce the background and spillover into other channels.
Can I use Zombie dyes for microscopy?

Zombie dyes tested in-house for microscopy applications will display data on the product technical datasheet. It should be noted that Zombie dyes may not work for dead cell discrimination in every microscopy application. Important considerations that may impact analysis are determining the signal level that constitutes a dead cell and identifying the proper plane to observe the dead cells.

Why can't I fix my cells prior to using Zombie dyes?

The fixation process can contort and alter the membrane of cells, effectively rendering them dead. Since the ability of the Zombie dyes to stain dead cells is correlated with cell permeability, your results may no longer be a valid representation of dead versus live cells.

Can I use Zombie dyes to detect apoptotic cells?

Yes, Zombie dyes can be used with apoptosis markers, such as Annexin V or Apotracker™ (shown below), to discriminate live, apoptotic, and dead cells.

One day-old C57BL/6 mouse thymocytes were stained with Apotracker™ Tetra Alexa Fluor® 647 and Zombie™ YG581. Zombie-dim/Apotracker™-positive cells are apoptotic, while double-positive cells are dead. Live cells are negative for both markers.

Can I use the UV laser to stimulate Zombie Aqua™? If so, can I then use it in conjunction with BV510™?

While we typically do not test Zombie Aqua™ with the UV laser, its excitation peak suggests it is effectively excited at 355 nm. However, we would not recommend using BV510™ off the violet laser and Zombie Aqua™ off the UV laser at the same time. Due to cross-beam excitation of BV510™ by the UV laser and the violet excitation of Zombie Aqua™, this would lead to significantly increased background and excessive compensation requirements.


How should I store Zombie dyes?

Store the Zombie dye kit at -20°C upon receipt. Do not open vials until needed. Once DMSO is added, use immediately or store at -20°C in a dry place and protected from light, preferably in a desiccator or in a container with desiccant for no more than one month.

Go To Top Version: 9    Revision Date: 12.18.2024

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account